Opicapone

Drug Profile

Opicapone

Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator BIAL
  • Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 18 May 2017 Ono Pharmaceutical plans a phase I trial in Healthy volunteers in Japan (JapicCTI-173583)
  • 19 Apr 2017 Bial plans a phase I trial for Parkinson's disease (In volunteers) (NCT03116295)
  • 14 Feb 2017 Neurocrine Biosciences has patent protection for Opicapone in USA (Neuroscience Biosciences form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top